



Kala Pharmaceuticals to Present at 2020 Webbush PacGrow Healthcare Virtual Conference

August 4, 2020

WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 4, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the 2020 Webbush PacGrow Healthcare Virtual Conference. Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals, is scheduled to present on Tuesday, August 11, 2020 at 1:10 p.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit "Events" in the "Investors" section of the Kala website at <http://kalarx.com>

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY™ mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date set for October 30, 2020.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200804005087/en/): <https://www.businesswire.com/news/home/20200804005087/en/>

Investor Contact:

Hannah Deresiewicz

hannah.deresiewicz@sternir.com

212-362-1200

Source: Kala Pharmaceuticals, Inc.